The post operative pain management market has seen considerable growth due to a variety of factors.
• The market size of postoperative pain management has seen a robust growth in the recent past. The projection is that it will expand from $37.03 billion in 2024 to $39.38 billion in 2025, marking a compound annual growth rate (CAGR) of 6.4%.
The past growth is accredited to factors like escalating demand for pain management medications, rising chronic disease prevalence, growing numbers of surgery-performing cancer patients, surge in traffic accident cases and corresponding trauma injuries, and an overall rise in the number of surgical procedures.
The post operative pain management market is expected to maintain its strong growth trajectory in upcoming years.
• The market for postoperative pain management is projected to experience significant expansion in the upcoming years. It'll escalate to $49.89 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 6.1%.
This projected expansion during the forecast period can be ascribed to factors such as the adoption of multimodal analgesic techniques, heightened requests for non-opioid analgesics, increased R&D activities, a rising emphasis on palliative care, and an uptick in the number of surgical procedures. Key trends for this period include the introduction of novel drugs, tailored treatment plans, advancements in technology, the incorporation of digital health tech, superior pain management solutions, and the inclusion of telemedicine.
The postoperative pain management market is forecasted to expand owing to the surge in surgical procedures. These procedures, conducted by skilled surgeons, aim to diagnose, manage or tackle diseases, injuries or conditions. The rise in such procedures is influenced by factors such as an ageing population, escalating chronic diseases, advancements in medical technology, better access to healthcare, and an increasing demand for elective surgeries. Postoperative pain management plays a pivotal role in faster recovery by effectively managing pain and improving patient comfort, thereby minimizing complications and fostering improved surgical outcomes. As an illustration, the UK Health Security Agency reported in December 2023, that there was a substantial increase in the number of coronary artery bypass graft surgeries in 2023, recording 27,524 surgeries, compared to preceding years. Consequently, the augmenting number of surgical procedures is leading to the growth of the postoperative pain management market.
The post operative pain management market covered in this report is segmented –
1) By Pain Type: Acute Pain, Moderate Pain, Severe Pain
2) By Drug Class: Opioids, Non-steroidal anti-inflammatory drugs (NSAIDs), Cyclooxygenase-2-selective inhibitors (COX-2 inhibitors), Other Drug Classes
3) By Route Of Administration: Injectable, Oral, Topical, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
5) By Application: Cancer Pain, Arthritic Pain, Neuropathic Pain, Musculoskeletal Pain, Migraine
Subsegments:
1) By Acute Pain: Non-Opioid Analgesics, Opioid Analgesics, Local Anesthetics, Other Acute Pain Treatments
2) By Moderate Pain: NSAIDs, Acetaminophen, Weak Opioids, Combination Therapies, Other Moderate Pain Treatments
3) By Severe Pain: Strong Opioids, Patient-Controlled Analgesia (PCA), Epidural Analgesia, Nerve Blocks, Other Severe Pain Treatments
Leading entities in the post-operative pain management market are directing their research and development resources towards technological advancements, namely cryoablation probes. These instruments use regulated cooling to target and lessen pain by focusing on specific nerves. Cryoablation probes function as medical tools that freeze and annihilate targeted nerve tissues or abnormal cells, typically to manage pain or to treat tumors. A case in point is AtriCure Inc., a medical device firm from the United States, which introduced the cryoSPHERE MAX in October 2024. This probe enhances post-operative pain management by temporarily numbing pain via targeted freezing of peripheral nerves. It boasts a cutting-edge design that diminishes freeze durations and optimizes tissue contact, thus providing more comprehensive and effective pain alleviation. This modern device features advancements in insulation, the use of Nitrous Oxide gas, tactile tissue response, and real-time temperature tracking.
Major companies operating in the post operative pain management market are:
• Johnson & Johnson
• Merck & Co. Inc.
• Bayer AG
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Cipla Inc.
• Hikma Pharmaceuticals PLC
• Mallinckrodt plc
• Pacira BioSciences Inc
• Endo International plc
• AFT Pharmaceuticals Limited
• Heron Therapeutics Inc.
• Cara Therapeutics Inc.
• Teikoku Pharma USA Inc
• Allay Therapeutics Inc
• PainReform Ltd
• Scilex Pharmaceuticals Inc.
• Taiwan Liposome Company Ltd
• Concentric Analgesics Inc.
• Durect Corporation
• Neumentum Inc.
• Trevena Inc.
• Virpax Pharmaceuticals Inc.
North America was the largest region in the postoperative pain management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post operative pain management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.